Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05725954
Other study ID # 50762
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2024
Est. completion date December 2026

Study information

Verified date February 2024
Source Nova Scotia Health Authority
Contact Michael Stewart, MD
Phone 1(902) 473-2222 xt. 2526
Email Michael.Stewart@Dal.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It can be challenging for Primary Healthcare Providers (PHCPs) to differentiate between IBS and more serious illnesses involving the GI tract, such as Crohn's disease, ulcerative colitis, or cancer. To help with diagnosis and treatment of IBS, evidence-based guidelines have been developed. However, they are not commonly used in primary care practice and PHCPs and patients often feel that GI specialist evaluation and endoscopy is required. The development of care pathways and clinical practice guidelines is essential to support the investigation and management of digestive diseases, such as IBS. The current pilot study is designed to assess the implementation and early comparative effectiveness of a Clinical Care Pathway for lower GI tract symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 2026
Est. primary completion date March 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Must be a general practitioner - Have a family practice in Nova Scotia, Canada - Utilize the platform 'virtual hallway' as part of current referral practices - Deliver care to patients with lower GI complaints Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
GUT LINK SmartPath
A virtual care delivery and referral support tool for primary healthcare providers.

Locations

Country Name City State
Canada QEII Health Sciences Centre Halifax Nova Scotia

Sponsors (2)

Lead Sponsor Collaborator
Michael Stewart Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of users Number of users (an indicator of prototype acceptability) month 3
Primary Number of users Number of users (an indicator of prototype acceptability) month 6
Primary Number of referrals Number of referrals from GPs to GI Department (an indicator of prototype acceptability) month 3
Primary Number of referrals Number of referrals from GPs to GI Department (an indicator of prototype acceptability) month 6
Primary Number of referrals per week Number of referrals per week from GPs to GI Department (an indicator of prototype acceptability) month 3
Primary Number of referrals per week Number of referrals per week from GPs to GI Department (an indicator of prototype acceptability) month 6
Primary Number of referrals per user Number of referrals per week from GPs to GI Department (an indicator of prototype acceptability) month 3
Primary Number of referrals per user Number of referrals per week from GPs to GI Department (an indicator of prototype acceptability) month 6
Primary Number of clicks per referral Number of clicks per referral from GPs to GI Department (an indicator of prototype acceptability) month 3
Primary Number of clicks per referral Number of clicks per referral from GPs to GI Department (an indicator of prototype acceptability) month 6
Primary Primary Healthcare Provider Satisfaction Thematic analysis of interviews of primary care providers will yield key themes related to satisfaction with the intervention. baseline (month 0)
Primary Primary Healthcare Provider Satisfaction Thematic analysis of interviews of primary care providers will yield key themes related to satisfaction with the intervention. month 6
Secondary Number referrals received as per prototype Number referrals received as per prototype (an implementation metric) month 3
Secondary Number referrals received as per prototype Number referrals received as per prototype (an implementation metric) month 6
Secondary Number of referrals received requiring troubleshooting Number of referrals received requiring troubleshooting (an implementation metric) month 3
Secondary Number of referrals received requiring troubleshooting Number of referrals received requiring troubleshooting (an implementation metric) month 6
Secondary Number of referrals aborted Number of referrals aborted (an implementation metric) month 3
Secondary Number of referrals aborted Number of referrals aborted (an implementation metric) month 6
Secondary Type of consult Type of consult (Full consult, specialist telephone advice, eConsult) month 3
Secondary Type of consult Type of consult (Full consult, specialist telephone advice, eConsult) month 6
Secondary Perceived appropriateness of the SmartPath Thematic analysis of interviews of primary care providers will yield key themes related to the perceived appropriateness of the intervention month 3
Secondary Perceived appropriateness of the SmartPath Thematic analysis of interviews of primary care providers will yield key themes related to the perceived appropriateness of the intervention month 6
Secondary physician self-efficacy rating physician self-efficacy rating, measured using the 'New General Self Efficacy Scale' (an effectiveness metric of GUT LINK Smartpath). Min score: 1, max score: 8. A higher score indicates a greater self-efficacy. month 3
Secondary physician self-efficacy rating physician self-efficacy rating, measured using the 'New General Self Efficacy Scale' (an effectiveness metric of GUT LINK Smartpath). Min score: 1, max score: 8. A higher score indicates a greater self-efficacy. month 6
Secondary Referral triage priority category Referral triage priority category will be collected from referrals through the pathway (an effectiveness metric of GUT LINK Smartpath). Referral triage categories to the GI department are: emergent, semi urgent, and non-urgent. month 3
Secondary Referral triage priority category Referral triage priority category will be collected from referrals through the pathway (an effectiveness metric of GUT LINK Smartpath). Referral triage categories to the GI department are: emergent, semi urgent, and non-urgent. month 6
Secondary Time from referral to specialist consultation Time from referral to specialist consultation, in weeks (an effectiveness metric of GUT LINK Smartpath) month 3
Secondary Time from referral to specialist consultation Time from referral to specialist consultation, in weeks (an effectiveness metric of GUT LINK Smartpath) month 6
Secondary Time from referral to diagnosis and treatment Time from referral to diagnosis and treatment, in weeks (an effectiveness metric of GUT LINK Smartpath) month 3
Secondary Time from referral to diagnosis and treatment Time from referral to diagnosis and treatment, in weeks (an effectiveness metric of GUT LINK Smartpath) month 6
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3